Olfactory Training for Mild Cognitive Impairment
(OTMCI Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if "Olfactory Training" (a therapy using smell exercises) can help individuals with mild cognitive impairment (MCI) improve their sense of smell, thinking skills, and daily functioning. MCI is an early stage of memory loss that often precedes Alzheimer's disease. Participants will be randomly assigned to either smell memory exercises or visual memory exercises for three months, with a follow-up at six months. The trial seeks individuals with MCI who notice memory issues in their daily life. As an unphased trial, this study offers a unique opportunity to contribute to research that could enhance daily life for those with MCI.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you are on nasally administered medications other than nasal steroids, you may not be eligible to participate.
What prior data suggests that olfactory training is safe for improving smell and thinking abilities?
Previous studies have shown that olfactory training can improve brain function and thinking skills. This training involves regularly smelling different scents. Research indicates that it can enhance thinking skills in individuals, regardless of their initial sense of smell.
The treatment appears well-tolerated, with no major safety issues reported. Participants undergoing olfactory training have not experienced significant negative effects, suggesting that the treatment is generally safe, even for those with mild memory or thinking problems.12345Why are researchers excited about this trial?
Researchers are excited about olfactory training for mild cognitive impairment because it offers a non-invasive approach to potentially boost cognitive function. Unlike standard treatments which primarily use medications like cholinesterase inhibitors to manage symptoms, olfactory training targets the brain's ability to process and recall smells, which is often one of the first senses affected in cognitive decline. By stimulating the olfactory pathways, this method could enhance memory and cognitive abilities without the side effects associated with many drugs. Additionally, the trial also includes visual memory training, providing a unique comparison of sensory-based cognitive interventions.
What evidence suggests that olfactory training could be effective for mild cognitive impairment?
This trial will compare Olfactory Memory Training with Visual Memory Training for individuals with mild cognitive impairment (MCI). Research has shown that smell training can help people regain their sense of smell. Although strong evidence is lacking that this training significantly improves thinking or memory in people with MCI, losing the sense of smell is a well-known early sign of Alzheimer's. Some studies suggest that using smell training to engage the brain might benefit mental health. Early research has shown positive effects, but further studies are needed to confirm these findings. If successful, this method could aid in early intervention for those at risk of Alzheimer's.12346
Who Is on the Research Team?
Jeffrey N Motter, PhD
Principal Investigator
Research Foundation for Mental Hygiene, Inc.
Are You a Good Fit for This Trial?
This trial is for individuals aged 55-89 with mild cognitive impairment (MCI), who have memory or other cognitive complaints and score below certain levels on a memory test. They must have an informant to provide updates on their functioning.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo Olfactory Memory Training or Visual Memory Training for 3 months
Follow-up
Participants are monitored for changes in cognitive, olfactory, and functional measures
What Are the Treatments Tested in This Trial?
Interventions
- Olfactory Training
Find a Clinic Near You
Who Is Running the Clinical Trial?
New York State Psychiatric Institute
Lead Sponsor
Jeffrey Motter
Lead Sponsor
Alzheimer's Association
Collaborator